Immunomodulatory agents
US10407502B2 · kind B2 · utility
5Cited by
5References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2015 |
| Grant date | Sep 10, 2019 |
| Priority date | — |
| Expiry date | Oct 2, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.